SCHEMBL24723929

SCHEMBL24723929

C=C/C=C\C(=C/C)NC(=O)/C=C/c1ccccc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC3 O15379 2/20 0.51
HDAC4 P56524 1/20 0.51
HDAC1 Q13547 1/20 0.51
HDAC2 Q92769 1/20 0.51
HDAC8 Q9BY41 1/20 0.51
HDAC6 Q9UBN7 1/20 0.51
HTT P42858 1/20 0.51
ALDH1A1 P00352 2/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
EGFR P00533 6/20 0.49
KMT2A Q03164 1/20 0.49
TDP1 Q9NUW8 3/20 0.48
NPC1 O15118 1/20 0.48
MAPT P10636 1/20 0.48
RAB9A P51151 1/20 0.48
MMP1 P03956 6/20 0.48
MMP2 P08253 6/20 0.48
MMP9 P14780 6/20 0.48
MAOA P21397 1/20 0.47
MAOB P27338 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26636136 0.81 HTT (0.54) HDAC3HDAC4HDAC1HDAC2HDAC8
SCHEMBL20445244 0.77 ALDH1A1 (0.42) HDAC3HDAC1HDAC2HDAC8HDAC6
SCHEMBL29060766 0.77 HDAC2 (0.76) HDAC3HDAC4HDAC1HDAC2HDAC8
SCHEMBL4029206 0.77 HDAC2 (0.76) HDAC3HDAC4HDAC1HDAC2HDAC8
SCHEMBL7663174 0.76 HDAC3 (0.63) HDAC3HDAC4HDAC1HDAC2HDAC8
SCHEMBL7656834 0.76 HDAC2 (0.63) HDAC3HDAC4HDAC1HDAC2HDAC8
SCHEMBL28440927 0.75 HDAC2 (0.73) HDAC3HDAC4HDAC1HDAC2HDAC8
SCHEMBL28440928 0.75 HDAC2 (0.73) HDAC3HDAC4HDAC1HDAC2HDAC8
SCHEMBL24292340 0.75 HDAC8 (0.45) HDAC3HDAC4HDAC1HDAC2HDAC8
SCHEMBL19403907 0.75 SMN1; SMN2 (0.47) ALDH1A1SMN1; SMN2KMT2ANPC1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220324805-A1 DRUG-INDUCED ACTIVATION OF THE REELIN SIGNALING SYSTEM UNIVERSITY OF SOUTH FLORIDA 2022-10-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220324805-A1 DRUG-INDUCED ACTIVATION OF THE REELIN SIGNALING SYSTEM LDLR, LRP6, PSEN2 HDAC3 946/4885HDAC4 2623/4885HDAC1 1721/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.